M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Phase 2

Completed

Conditions: Distal Urethral Cancer
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Proximal Urethral Cancer
Recurrent Bladder Cancer
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
Recurrent Urethral Cancer
Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
Stage III Bladder Cancer
Stage IV Bladder Cancer
Transitional Cell Carcinoma of the Bladder

Interventions: Drug: Gemcitabine hydrochloride
Drug: Paclitaxel
Drug: Doxorubicin hydrochloride
Drug: Pegfilgrastim

First Posted Date: 2007-05-24

Last Posted Date: 2020-10-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00478361

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield, Springfield, Missouri, United States

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

Phase 1

Terminated

Conditions: Central Nervous System Tumors
Brain Tumors

Interventions: Drug: Gallium-67 Citrate (Ga-67)
Drug: In-111 DTPA (In-111 pentetate)

First Posted Date: 2007-05-23

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00477503

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

School Reintegration Outcomes in Pediatric Cancer Patients

Completed

Conditions: Pediatric Cancers

Interventions: Behavioral: Questionnaires

First Posted Date: 2007-05-23

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 91

Registration Number: NCT00477256

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Locus of Control and Spirituality in Palliative Care Patients

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-05-23

Last Posted Date: 2017-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00477243

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Phase 1

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dexamethasone
Drug: Doxorubicin
Drug: Methotrexate
Biological: Rituximab
Drug: Vincristine

First Posted Date: 2007-05-23

Last Posted Date: 2022-01-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 107

Registration Number: NCT00477412

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Health Habits and Cancer Risk Comparison Among Migrant Sri Lankans and Sri Lankans

Withdrawn

Conditions: Acculturation

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-05-22

Last Posted Date: 2015-08-28

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00476580

Locations: 🇱🇰
University of Peradeniya, Peradeniya, Sri Lanka
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
City of Houston Department of Health and Human Services, Houston, Texas, United States

Epidemiology Controls Using Healthy Participants

Conditions: Healthy

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-05-22

Last Posted Date: 2019-05-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1500

Registration Number: NCT00476632

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Spectral Diagnosis of Cutaneous Malignancy

Completed

Conditions: Skin Cancer

Interventions: Device: Spectral Diagnosis Probe

First Posted Date: 2007-05-22

Last Posted Date: 2019-05-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 350

Registration Number: NCT00476905

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer

Recruiting

Conditions: Inflammatory Breast Carcinoma
Second Primary Malignant Neoplasm
Invasive Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Other: Interview
Other: Medical Chart Review
Other: Questionnaire Administration

First Posted Date: 2007-05-22

Last Posted Date: 2024-10-08

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1200

Registration Number: NCT00477100

Locations: 🇺🇸
Banner - MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Scripps - MD Anderson Cancer Center, La Jolla, California, United States
🇺🇸
Banner - MD Anderson Cancer Center - Northern Colorado, Greeley, Colorado, United States

and more 7 locations

Long-Term Follow Up Study for AMD3100 Patients

Completed

Conditions: Myeloma

Interventions: Other: Telephone Questionnaire

First Posted Date: 2007-05-21

Last Posted Date: 2012-07-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT00476294

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy